SCHEMBL10189450

SCHEMBL10189450

CCCOC(=O)Nc1cc(-c2csnc2-c2cc(C)c(OC)c(OC)c2)ccc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
EGFR P00533 4/20 0.39
KDR P35968 4/20 0.39
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC3 O15379 1/20 0.38
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 1/20 0.37
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
GAA P10253 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12118594 0.94 MAPT (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189449 0.93 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189445 0.87 NPSR1 (0.47) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL617828 0.87 RXFP1 (0.40) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189237 0.86 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4EHSD17B10LMNA
SCHEMBL12338917 0.84 MAPT (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189442 0.83 NPSR1 (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189439 0.83 NPSR1 (0.39) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL10189378 0.82 LMNA (0.38) ALDH1A1HPGDHSD17B10MAPTLMNA
SCHEMBL10189443 0.82 POLB (0.41) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUN LIJUN (US) 2013-08-08 US disclosed
US-8399435-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-03-19 US disclosed
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040937-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885KDM4E 2492/4885
US-20130203824-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885SMN1; SMN2 3188/4885KDM4E 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.